Recent work has demonstrated that the formation of platelet neutrophil complexes (PNCs) affects inflammatory tissue injury. Vasodilator-stimulated phosphoprotein (VASP) is crucially involved into the control of PNC formation and myocardial reperfusion injury. Given the clinical importance of hepatic IR injury we pursued the role of VASP during hepatic ischemia followed by reperfusion. We report here that VASP−/− animals demonstrate reduced hepatic IR injury compared to wildtype (WT) controls. This correlated with serum levels of lactate dehydrogenase (LDH), aspartate (AST) and alanine (ALT) aminotransferase and the presence of PNCs within ischemic hepatic tissue and could be confirmed using repression of VASP through siRNA. In studies employing bone marrow chimeric mice we identified hematopoietic VASP to be of crucial importance for the extent of hepatic injury. Phosphorylation of VASP on Ser153 through Prostaglandin E1 or on Ser235 through atrial natriuretic peptide resulted in a significant reduction of hepatic IR injury. This was associated with a reduced presence of PNCs in ischemic hepatic tissue. Taken together, these studies identified VASP and VASP phosphorylation as crucial target for future hepatoprotective strategies.
Citation: Köhler D, Birk P, König K, Straub A, Eldh T, Morote-Garcia JC, et al. (2011) Phosphorylation of Vasodilator-Stimulated Phosphoprotein (VASP) Dampens Hepatic Ischemia-Reperfusion Injury. PLoS ONE 6(12): e29494. doi:10.1371/journal.pone.0029494
Editor: Holger K. Eltzschig, University of Colorado Denver, United States of America
Received: October 21, 2011; Accepted: November 29, 2011; Published: December 22, 2011
Copyright: © 2011 Köhler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant to P.R. from the Deutsche Forschungsgemeinschaft (DFG; grant number DFG-RO 3671/4-1 and DFG-RO 3671/5-1). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Surgical procedures such as liver transplantation, partial hepatic resection, hepatic tumor surgery or trauma repair may induce hepatic ischemia-reperfusion (IR) injury which is associated with clinically significant reduced liver function . A pathophysiological consequence of the cessation of blood supply followed by reperfusion is cellular damage within the ischemic areas. Several underlying mechanisms are involved in this process such as microvascular dysfunction and enhanced leukocyte-endothelial cell adhesion during the early stages of reperfusion . In addition, triggered by inflammatory mediators (e.g. cytokines) neutrophils are activated to cross the endothelial barrier and translocate into hepatic tissue. This results in the release of enzymes and reactive oxygen species that aggravate the associated tissue injury within the hepatic tissue , , .
Recent work has described an important role for platelet-neutrophil complexes (PNCs) during inflammatory and ischemic tissue injury. In a study by Zarbock et al. the authors demonstrate that the degree of lung injury can be significantly attenuated if the formation of PNCs is blocked . Furthermore, through platelet depletion or the injection of activated platelets the role of platelet-neutrophil complexes (PNCs) that are primed for adhesion, migration, phagocytosis and intracellular killing was further delineated in the past , , . In a recent study we were able to describe the role of PNCs during myocardial IR injury . In this study we identified vasodilator-stimulated phosphoprotein (VASP), a central cytoskeleton protein affecting actin dynamics, to be a crucial regulator of PNC formation during the reperfusion phase. Phosphorylation of VASP on serine 157 (Ser157) through prostaglandin E1 (PGE1) or on serine 239 (Ser239) through atrial natriuretc peptide (ANP) resulted in a significant attenuation of this PNC formation , . Previous work has implicated a hepatoprotective potential of PGE1 in cirrhotic patients and in experimental in vivo studies. This hepatoprotective potential was also described for ANP with a reduction of hepatic apoptosis and tissue injury through an ANP infusion during hepatic reperfusion , , , .
Given the importance of PNCs for the extent of inflammatory organ injury and the fact that VASP phosphorylation affects the formation of PNCs, we analyzed the role of VASP and VASP phosphorylation during hepatic IR injury. In vivo experimental data depicted a significant reduction of hepatic IR injury in VASP−/− mice associated with a reduced presence of PNCs. Targeted repression of VASP using siRNA confirmed these results. Hepatic IR experiments in bone marrow chimeric animals identified hematopoietic VASP expression to affect the extent of hepatic IR injury. Furthermore, phosphorylation of VASP affects the formation of PNCs and as such the extent of hepatic IR injury.
Materials and Methods
All animal protocols were in accordance with the German guidelines for use of living animals and were approved by the Institutional Animal Care and Use Committee of the Tübingen University Hospital and the Regierungspräsidium Tübingen. VASP−/− mice were generated, validated and characterized as described previously . The WT controls (C57BL/6 mice) were bred as littermates of VASP−/− mice.
Murine model of hepatic ischemia
VASP−/− mice and littermate controls were selected to be similar in age-, gender- and weight. After anesthesia was induced animals were placed on a temperature-controlled and heated table to maintain body temperature at 37°C. Following midline laparotomy the liver was exposed. Ligation of the hepatic artery occured in the ligamentum hepatoduodenale, where the portal triad was completely and reversible occluded. During the ischemic period the lobus dexter and lobus caudatus remained perfused via separate influx and efflux, as described previously . Tissue damage was determined through blood serum levels of lactate dehydrogenase (LDH) (Randox, Crumlin, United Kingdom), aspartate (AST) and alanine aminotransferase (ALT) (Teco Diagnostics, Anaheim, USA).
Pharmacological compounds used
PGE1 (0.42 µg/kg/h, Sigma-Aldrich, Munich, Germany), atrial natriuretic peptide (ANP) (0.12 µg/kg/h, Sigma-Aldrich, Munich, Germany) or vehicle (0.9% NaCl) was administered by intravenous infusion beginning 5 min prior to reperfusion and continuing 1 hour during reperfusion.
In vivo small interfering RNA Repression
To achieve in vivo repression of VASP we used 2.6 µg/g body weight VASP ON-TARGETplus® SMARTpool Mouse siRNA dissolved in 5% Glucose-solution. As control served non-targeting siRNA (Thermo Scientific Dharmacon, Dreieich, Germany) with at least four mismatches to any human, murine or rat gene. The siRNA target sequences of the VASP pool were, J-046659-17 with target sequence UGC CAU UGC UGG AGC CAA A, J-046659-18 with target sequence AGG AAA UCA UCG AAG UCU U, J-046659-19 with target sequence GGG CUA CUG UGA UGC UUU A, J-046659-20 with target sequence GAG CUG AGG AAG CGG GGU U. SiRNA was administered 24 hours before ischemia or in subset of experiments 5 min before onset of reperfusion.
Western blots for VASP and VASP phosphorylation
Mice were injected for stimulation with either 0.42 µg PGE1 or 0.12 µg ANP and blood was taken after 15 min. After spinning at 14,000×g for 10 min to remove cell debris, the pellet was resuspended in RIPA buffer and protein concentration was measured. For siRNA experiments the knockdown was validated by taking blood from mice after 24 h incubation. Primary antibodies were polyclonal anti-VASP (Cell Signaling), polyclonal anti-pVASP153 (Cell Signaling) and anti-pVASP235 (Cell Signaling). Loading conditions were controlled by polyclonal anti-GAPDH (Santa Cruz Biotechnology).
Immunohistochemistry of neutrophils and platelets in murine tissue
Immunohistochemical staining was performed with Vectastain® ABC Kit (Linaris, Wertheim, Germany). After inhibiting the non-specific binding sites with avidin blocking solution (Vector Laboratories, CA, USA) the sections were incubated with primary antibody (polyclonal rabbit anti-mouse CD41, Abcam) over night at 4°C. Tissue sections were then incubated with biotinylated anti rabbit IgG for 1 hour followed by Vectastain® ABC Reagent for 30 minutes, and then developed using DAB substrate. For neutrophil staining, the procedure was repeated using rat anti-mouse neutrophil antibody (rat antimouse Ly-6B2 clone 7/4, AbD Serotec) and histogreen as substrate (Linaris). Counterstaining was performed using nuclear fast red (Linaris).
Triphenyltetrazolium chloride staining
After 30 min ischemia and 3 h reperfusion parts of the lobus medianus were excised washed in ice-cold 0.9% saline, placed on parafilm, frozen at −20°C for 30 min and cut into 1 mm slices. The slices were incubated with 1% TTC at 37°C for 30 min and fixed in 10% formalin. As previously described TTC stains all cells red except those that are depleted in NADPH and therefore allows to distinguish viable tissue from ischemic tissue .
Generation of bone marrow (BM) chimeras
In short, male donor mice (8–10 weeks old, 20–25 g) were euthanized, marrow harvested by flushing the marrow cavity and bone marrow cells were then centrifuged at 400×g for 5 min, resuspended and counted. Recipient mice (8–10 weeks of age, 20–25 g) were irradiated with a total dose of 10 Gy from a 137Cs source. Immediately after irradiation, 107 BM cells/recipient were injected in 0.15 ml 0.9% sodium chloride into the tail vein. The resulting chimeric mice were housed in microisolators for at least 6 weeks before experimentation and fed with water containing tetracycline (100 mg/l) in the first two weeks following BM transplantation. Bone marrow cells were transplanted to generate (1) [WT → WT] (2) [VASP−/− → VASP−/−] mice as controls and (3) [WT → VASP−/−] (4) [VASP−/− → WT] chimeric mice .
For flow cytometry blood was gently collected by puncture of the hepatic portal vein and immediately anticoagulated. For the determination of PNCs citrated whole blood samples were incubated with a monoclonal anti-CD42b-FITC antibody (clone Xi1.G5, Emfret Analytics) and with a monoclonal anti-CD15-PE antibody (clone C3D-1 Santa Cruz Biotechnology). For the determination of GPIIb/IIIa activation, citrated whole blood samples were incubated with anti-CD42b-FITC Ab (Emfret) and with the activation-specific monoclonal Jon-A-PE Ab (clone Jon-A, Emfret). After 30 minutes incubation at 37°C, samples were fixed using CellFix (BD Biosciences). Flow cytometry was performed on a FACScan cytometer (BD Biosciences) and PNC formation as well as GPIIb/IIIa activation were analyzed according to previously described principles , . In all experiments, suitable isotype Abs were used to adjust for nonspecific Ab binding.
All values are expressed as mean ± SEM. Using Kolmogorov-Smirnov test we could show that the measured values were approximately normally distributed. Statistical significance was determined using one-way ANOVA followed by Bonferroni's multiple-comparison test. Student's t test was used where appropriate. A value of P<0.05 was considered significant.
Hepatic IR injury and PNC infiltration is attenuated in VASP−/− mice
In a model of murine hepatic IR injury we exposed previously characterized VASP−/− and controls to 30 minutes of partial liver ischemia followed by 3 hours of reperfusion . Following this VASP−/− mice demonstrated a significant reduction of LDH, AST and ALT serum levels compared to controls (Figure 1 A, B and C). TTC staining of liver tissue sections confirmed these results (Figure 1 ). Following double staining for PNCs we found a reduced presence of PNCs within tissue of VASP−/− animals compared to controls (Figure 1 E). To determine the presence of PNCs within the blood of these animals we determined the number of PNCs in whole blood samples after 30 minutes ischemia. We found that the number of PNCs was significantly lower in VASP−/− animals compared to WT controls (Figure S1 A). We also found reduced presence of the active state of the murine GPIIb/IIIa receptor on the platelet surface of VASP−/− animals compared to WT controls, thus confirming previously published data from our group (Figure S1 B).
A) LDH-serum levels of VASP−/− and WT mice after 30 minutes ischemia and 3 hours reperfusion in U/L. B) Correlating serum levels of AST and C) ALT of VASP−/− and WT animals. D) Representative TTC stained liversections of VASP−/− and WT animals E) Histological images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic tissue of VASP−/− and WT animals (Data are shown as Mean ± SEM, n = 6, *P<0.05; ***P<0.001 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
To gain further insight into the specific role of VASP we employed gene targeted repression using siRNA and injected animals 24 hours prior to the start of the experiment with siVASP or non-targeting siRNA (siSCR). Repression of VASP was controlled by Western Blot analysis (Figure S2). We then subjected the siRNA treated animals to the hepatic IR model and found reduced LDH, AST and ALT serum levels in siVASP treated animals compared to siSCR controls (Figure 2 A, B and C). TTC stained liver tissue sections corroborated the reduced tissue damage in the siVASP group (Figure 2 D). This reduction of decreased hepatic damage was associated with a reduced presence of PNCs within the affected hepatic tissue (Figure 2 E). Using siVASP immediately during the reperfusion phase however failed to show a clear effect on IR injury (Figure S6 A, B, C, D and E).
A) LDH-serum levels after hepatic IR in in-vivo targeted repression of VASP with siRNA (siVASP) or non-targeting siRNA (siSCR) B) Correlating serum levels of AST and C) ALT of siVASP and siSCR treated WT animals. D) Representative TTC stained liversections of both groups. E) Histological images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic tissue of siVASP and siSCR treated animals (Data are shown as Mean ± SEM, n = 6, *P<0.05; **P<0.01 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
Hematopoietic VASP repression dampens hepatic IR injury and PNC infilatration
To gain further insight into the underlying mechanism, we generated chimeric animals to identify whether tissue specific or hematopoietic expression would be involved in the previously observed results. For this, we transferred hematopoietic cells of VASP−/− mice into WT animals (VASP−/−→WT) and WT hematopoietic cells in VASP−/− mice (WT→VASP−/−), with WT→WT and VASP−/−→VASP−/− transplanted mice as controls. To control successful transfer of bone marrow we used western blot analysis (Figure S3). The generated bone marrow chimeric animals were then subjected to 30 minutes ischemia followed by 3 hours reperfusion. Comparison of the serum parameters LDH, AST and ALT in bone marrow chimeric mice demonstrated reduced damage in the hematopoietic VASP−/− (VASP−/−→WT; VASP−/−→VASP−/−) animals (Figure 3 A, B and C). TTC stained liver tissue slices of the different animal groups confirmed the serum measurements (Figure 3 D). Additionally we found a reduced presence of PNCs within the hepatic tissue of hematopoietic VASP−/− mice compared to hematopoietic WT animals. This correlated with decreased hepatic tissue injury (Figure 3 E). With these findings we were able to confirm the findings of a previous study demonstrating the role of VASP during myocardial ischemia-reperfusion . In this study we found that VASP within platelets is crucially important for the observed protective role of VASP repression during IR injury.
A) LDH-serum levels in chimeric animals (VASP−/−→WT and WT→VASP−/−) and control transplanted animals after 30 minutes of hepatic ischemia followed by 3 hours reperfusion. B) Correlating serum levels of AST and C) ALT of the chimeric and control animals D) Representative TTC stained liversections of ischemic tissue. E) Representative histological images of infracted hepatic areas of infiltrated platelet-neutrophil complexes (neutrophil = blue; platelets = black) of chimeric animals (VASP−/−→WT and WT→VASP−/−) and control transplanted (WT→WT and VASP−/−→ VASP−/−) animals (Data are shown as Mean ± SEM, n = 6, *P<0.05; **P<0.01; ***P<0.001 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
Phosphorylation of VASP on Ser153 using PGE1 dampens hepatic IR injury
PGE1 induces solid human VASP phosphorylation on Ser157. In an initial experiment we evaluated possible hemodynamic changes following perfusion with PGE1 but did not find a significant change of hemodynamic parameters, however we found the expected murine VASP Ser153 phosphorylation. We also observed a cross phosphorylation on VASP Ser235 through PGE1 (Figure S4 and S5). The PGE1 infusion resulted in a significant reduction in LDH, AST and ALT (Figure 4 A, B and C) in WT mice, which was not present in VASP−/− animals. TTC staining confirmed the results of the serum enzyme levels demonstrating reduced hepatic IR injury (Figure 4 D). We then proceeded to identify the presence of PNCs within hepatic tissue of these animals, and found that WT animals treated with PGE1 had a minimal number of PNCs in comparison to vehicle treated and PGE1 treated VASP−/− mice (Figure 4 E).
A) LDH-serum levels in WT and VASP−/− animals after 30 minutes of hepatic ischemia followed by 3 hours reperfusion with infusion of saline (vehicle) or PGE1 during reperfusion. B) Correlating serum levels of AST and C) ALT of vehicle or PGE1 treated WT and VASP−/− animals. D) Representative TTC stained liversections of ischemic tissue. E) Histological images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic liver lobes of vehicle or PGE1 treated WT and VASP−/− animals (Data are shown as Mean ± SEM, n = 6, *P<0.05; **P<0.01; ***P<0.001 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
Phosphorylation of VASP on Ser235 using ANP attenuates hepatic IR injury
Atrial natriuretic peptide induces human VASP Ser239 phosphorylation in a cGMP dependent fashion . To evaluate whether this phosphorylation site also holds protective potential we initially tested for the expected phosphorylation of murine VASP at Ser235 (Figure S5). To preclude possible hemodynamic changes following ANP perfusion we determined the blood pressure values in ANP treated animals but did not find a significant change of hemodynamic parameters (Figure S4). When using ANP to induce VASP Ser235 phosphorylation in the reperfusion period we also found a significant reduction of serum LDH, AST and ALT levels in WT mice. This was not observed in the VASP−/− mice (Figure 5 A, B and C). TTC staining of liver sections corroborated our findings (Figure 5 D) and correlated with a reduced number of PNCs within the hepatic tissue of WT animals treated with ANP compared to vehicle treated and VASP−/− mice (Figure 5 E).
A) LDH-serum levels in WT and VASP−/− animals after 30 minutes of hepatic ischemia followed by 3 hours reperfusion with infusion of saline (vehicle) or ANP during reperfusion. B) Correlating serum levels of AST and C) ALT of vehicle or ANP treated WT and VASP−/− animals. D) Representative TTC stained liversections of ischemic tissue. E) Histological images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic liver lobes of vehicle or ANP treated WT and VASP−/− animals (Data are shown as Mean ± SEM, n = 6, *P<0.05; **P<0.01; ***P<0.001 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
We have previously demonstrated that the formation of PNCs can be influenced through the expression and phosphorylation of VASP during ischemia-reperfusion of the myocardium . However, the role of VASP during hepatic IR injury remained unclear to date. As an extension of our previous work we demonstrate here that hepatic IR injury is significantly influenced through VASP expression and VASP phosphorylation. This finding was associated with a reduced presence of PNCs within hepatic tissue of VASP−/− mice and associated with reduced hepatic injury following reperfusion.
Tissue injury during an acute inflammatory process or ischemia is significantly affected by the formation of PNCs. Previous work by Zarbock et al. has recognized the role of PNCs during acute lung injury and an inhibition of PNC formation results in a marked decrease of pulmonary injury and improves pulmonary function . Weissmüller et al. demonstrated that PNCs are translocated across the intestinal barrier and that the translocated platelets are functionally sound to release their contents , . In a recent study of our group, we were able to demonstrate that PNCs are translocated into ischemic myocardium following reperfusion . In this study we found that the formation of PNCs was significantly dependent on the phosphorylation of VASP. The phosphorylation of VASP achieved through ANP or PGE1 resulted in a reduction of GP IIb/IIIa activation on the surface of platelets and in a reduced formation of PNCs between platelets and neutrophils. As a result, the number of circulating PNCs is significantly attenuated and a reduced number of PNCs is translocated into ischemic tissue to aggravate the reperfusion injury. Previous work has shown that the extent of hepatic IR injury is also determined by the activation status of platelets. Cywes et al. demonstrated that an inactivation of platelets with formaldehyde significantly reduces the extent of hepatic IR injury. Furthermore, an activation of platelets resulted in an increased hepatic IR injury . A crucial determinant of the adherence of platelets on the endothelial surface is P-selectin. Animals deficient of P-selectin demonstrate reduced hepatic reperfusion injury following ischemia . Furthermore, the adhesion of platelets to the hepatic endothelium through fibrinogen deposition on endothelial ICAM-1 aggravates hepatic IR injury . Fibrinogen binding to platelets is mediated by the GP IIb/IIIa receptor, yet the surface expression of this receptor is significantly affected by the phosphorylation of VASP . Yadav et al. also demonstrated that neutrophils are important contributors to hepatic IR injury and that the recruitment to the hepatic tissue is dependent on P-selectin . In addition, the inactivation of neutrophils through a MAC-1 antibody results in a significant reduction of hepatic IR injury, this further supports the fact that an interaction of neutrophils with platelets is an important determinant of IR injury within the liver and our results are in accordance with these previous studies .
In the presented study, we used ANP to selectively induce phosphorylation of VASP on Ser235 and PGE1 to induce VASP phosphorylation on Ser153 , . The protective role of a pharmacological intervention with PGE1 or ANP during hepatic IR injury was demonstrated by several investigators previously. Hafez et al. were able to show that an infusion of PGE1 resulted in reduced expression of endothelial adhesion molecules such as ICAM within the liver and that this intervention resulted in a reduction of the associated hepatic IR injury . This is in line with previous findings demonstrating a reduction of IR injury and an attenuation of intrahepatic inflammation through PGE1 , . A protective role of an intervention with ANP during hepatic IR injury was initially described by Bilzer et al. . The positive effect of ANP on intrahepatic inflammation and tissue injury was also confirmed by several other investigators , . Our results are in accordance with these previous findings demonstrating a protective role for PGE1 and ANP during hepatic IR injury. PGE1 and ANP phosphorylate VASP in platelets and as such inactivate these platelets. The phosphorylation of VASP reduces platelet activity and the secretion of their contents. In addition the expression of L-selectin on the surface of endothelial cells is attenuated through a phosphorylation of VASP, which reduces the attachment of inflammatory cells to the endothelial surface. In a previous study we were able to demonstrate that tissue specific repression of VASP increases inflammatory tissue injury . Given the fact that we were able to achieve a reduction of hepatic reperfusion injury by approximately 50% demonstrates that tissue specific VASP holds additional protective function, yet this was not the focus of this investigation. Yet we report here for the first time that the observed protective effect of PGE1 or ANP during hepatic IR injury is mediated through the phosphorylation of the target protein VASP. This is undermined by the fact that PGE1 or ANP were not effective in VASP−/− animals.
In summary, the results of our study are in line with previous investigations demonstrating the importance of PNCs for the extent of inflammatory tissue injury and confirm that an intervention with PGE1 or ANP might be tissue protective during hepatic IR injury. VASP phosphorylation on Ser153 or Ser235 in mice resulted in reduced formation of PNCs and as a result the extent of hepatic IR injury. This work therefore furthers the understanding of the role of VASP during hepatic IR injury and might result in novel therapeutic strategies in the future.
VASP–deficient animals demonstrate reduced PNC formation and attenuated activation of GP IIb/IIIa receptor during hepatic IR injury. A) VASP−/− and WT mice were subjected to 30 minutes hepatic ischemia. Number of PNCs was determined using anti-CD42b-FITC Ab and anti-CD15-PE Ab after ischemia. B) Activation status of the murine GPIIb/IIIa receptor evaluated with the activation-specific Jon-A-PE-Ab during flow cytometry. (Data are shown as Mean±SEM, n = 4; **P<0.01; ***P<0.001 as indicated).
VASP protein expression in WT animals following siRNA injection. Westernblot analysis of hepatic tissue in WT animals 24 hours post siVASP or siSCR injection (n = 3).
VASP protein expression in chimeric animals. Western blot analysis of chimeric animals following BM transplantation demonstrating VASP expression in hepatic tissue or whole blood of WT→WT (control) transplanted animals, hematopoietic WT into VASP−/− animals (WT→VASP−/−), hematopoietic VASP−/− in WT animals (VASP−/−→WT) and VASP−/−→VASP−/− transplanted control animals (Pooled samples of n = 4/ group).
Hemodynamic values determined during the experimental protocol. Animals were cannulated with a catheter into the carotid artery and blood pressure measurements determined during anesthesia, ischemia, reperfusion, injection of atrial natriuretic peptide (ANP) or prostanglandin E1 ( PGE1) (All Data are Mean ± SEM, n = 6).
VASP phosphorylation following PGE1 or ANP treatment. Western blots from whole blood samples from WT mice taken 15 minutes following injection with either prostaglandin E1 (PGE1) or atrial natriuretic peptide (ANP) controlled for phosphorylation at murine VASP Ser153 through PGE1 and at murine VASP Ser235 through ANP (Pooled samples of n = 4/ group).
Liver IR injury in siRNA treated WT animal during reperfusion. A) LDH-serum levels following hepatic IR in in-vivo targeted repression (onset 5 min previous reperfusion) of VASP with siRNA (siVASP) or non-targeting siRNA (siSCR) B) Correlating serum levels of AST and C) ALT of siVASP and siSCR treated WT animals. D) Representative TTC stained images liver sections of both groups. E) ) Histological images of platelet-neutrophil complexes (neutrophil = blue; platelet = black) in tissue sections of ischemic liver lobes of siVASP and siSCR treated animals (Data are shown as Mean ± SEM, n = 6, *P<0.05 as indicated, tissue sections magnification x400 and x1000 with detail sector magnification, n = 3, one representative of 3 individual experiments is demonstrated).
Conceived and designed the experiments: PR DK. Performed the experiments: DK PB AS KK TE JCM. Analyzed the data: DK PB AS. Contributed reagents/materials/analysis tools: TE. Wrote the paper: PR DK.
- 1. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Pina E, Geller DA (2008) Factors in the pathophysiology of the liver ischemia-reperfusion injury. J Surg Res 147: 153–159.
- 2. Carden DL, Granger DN (2000) Pathophysiology of ischaemia-reperfusion injury. J Pathol 190: 255–266.
- 3. Vollmar B, Richter S, Menger MD (1997) Liver ischemia/reperfusion induces an increase of microvascular leukocyte flux, but not heterogeneity of leukocyte trafficking. Liver 17: 93–98.
- 4. Wang JH, Redmond HP, Watson RW, Bouchier-Hayes D (1995) Role of lipopolysaccharide and tumor necrosis factor-alpha in induction of hepatocyte necrosis. Am J Physiol 269: G297–304.
- 5. Walsh KB, Toledo AH, Rivera-Chavez FA, Lopez-Neblina F, Toledo-Pereyra LH (2009) Inflammatory mediators of liver ischemia-reperfusion injury. Exp Clin Transplant 7: 78–93.
- 6. Zarbock A, Singbartl K, Ley K (2006) Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116: 3211–3219.
- 7. Xu Y, Huo Y, Toufektsian MC, Ramos SI, Ma Y, et al. (2006) Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 290: H692–699.
- 8. Kornerup KN, Salmon GP, Pitchford SC, Liu WL, Page CP (2010) Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. J Appl Physiol 109: 758–767.
- 9. Peters MJ, Dixon G, Kotowicz KT, Hatch DJ, Heyderman RS, et al. (1999) Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 106: 391–399.
- 10. Kohler D, Straub A, Weissmuller T, Faigle M, Bender S, et al. (2011) Phosphorylation of Vasodilator-Stimulated Phosphoprotein Prevents Platelet-Neutrophil Complex Formation and Dampens Myocardial Ischemia-Reperfusion Injury. Circulation.
- 11. Benz PM, Blume C, Seifert S, Wilhelm S, Waschke J, et al. (2009) Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci.
- 12. Ibarra-Alvarado C, Galle J, Melichar VO, Mameghani A, Schmidt HH (2002) Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol Pharmacol 61: 312–319.
- 13. Sugawara Y, Kubota K, Ogura T, Esumi H, Inoue K, et al. (1998) Protective effect of prostaglandin E1 against ischemia/reperfusion-induced liver injury: results of a prospective, randomized study in cirrhotic patients undergoing subsegmentectomy. J Hepatol 29: 969–976.
- 14. Hafez T, Moussa M, Nesim I, Baligh N, Davidson B, et al. (2007) The effect of intraportal prostaglandin E1 on adhesion molecule expression, inflammatory modulator function, and histology in canine hepatic ischemia/reperfusion injury. J Surg Res 138: 88–99.
- 15. Gerwig T, Meissner H, Bilzer M, Kiemer AK, Arnholdt H, et al. (2003) Atrial natriuretic peptide preconditioning protects against hepatic preservation injury by attenuating necrotic and apoptotic cell death. J Hepatol 39: 341–348.
- 16. Kulhanek-Heinze S, Gerbes AL, Gerwig T, Vollmar AM, Kiemer AK (2004) Protein kinase A dependent signalling mediates anti-apoptotic effects of the atrial natriuretic peptide in ischemic livers. J Hepatol 41: 414–420.
- 17. Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, et al. (1999) Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 96: 8120–8125.
- 18. Hart ML, Much C, Kohler D, Schittenhelm J, Gorzolla IC, et al. (2008) Use of a hanging-weight system for liver ischemic preconditioning in mice. Am J Physiol Gastrointest Liver Physiol 294: G1431–1440.
- 19. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, et al. (1981) Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101: 593–600.
- 20. Henes J, Schmit MA, Morote-Garcia JC, Mirakaj V, Kohler D, et al. (2009) Inflammation-associated repression of vasodilator-stimulated phosphoprotein (VASP) reduces alveolar-capillary barrier function during acute lung injury. FASEB J 23: 4244–4255.
- 21. Köhler D, Straub A, Weissmüller T, Faigle M, Bender S, et al. (2011) Phosphorylation of vasodilator-stimulated phosphoprotein (VASP) prevents platelet-neutrophil complex formation and dampens myocardial ischemia-reperfusion injury. Circulation in print.
- 22. Straub A, Krajewski S, Hohmann JD, Westein E, Jia F, et al. (2011) Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol 31: 1607–1616.
- 23. Chen H, Levine YC, Golan DE, Michel T, Lin AJ (2008) Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem 283: 4439–4447.
- 24. Weissmuller T, Campbell EL, Rosenberger P, Scully M, Beck PL, et al. (2008) PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 118: 3682–3692.
- 25. Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, et al. (2007) CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116: 1784–1794.
- 26. Cywes R, Harvey PR, Packham MA, Cameron R, Strasberg SM (1996) The influence of prostaglandin E1 on platelet adherence and injury in preserved rat liver allografts. Liver Transpl Surg 2: 23–36.
- 27. Khandoga A, Biberthaler P, Enders G, Teupser D, Axmann S, et al. (2002) P-selectin mediates platelet-endothelial cell interactions and reperfusion injury in the mouse liver in vivo. Shock 18: 529–535.
- 28. Khandoga A, Biberthaler P, Enders G, Axmann S, Hutter J, et al. (2002) Platelet adhesion mediated by fibrinogen-intercelllular adhesion molecule-1 binding induces tissue injury in the postischemic liver in vivo. Transplantation 74: 681–688.
- 29. Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder TF, et al. (1999) P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology 29: 1494–1502.
- 30. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, et al. (1993) Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology 17: 915–923.
- 31. Comerford KM, Lawrence DW, Synnestvedt K, Levi BP, Colgan SP (2002) Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability. Faseb J.
- 32. Hossain MA, Hamamoto I, Wakabayashi H, Goda F, Kobayashi S, et al. (1999) Experimental study of the effect of intraportal prostaglandin E1 on hepatic blood flow during reperfusion after ischaemia and hepatectomy. Br J Surg 86: 776–783.
- 33. Natori S, Fujii Y, Kurosawa H, Nakano A, Shimada H (1997) Prostaglandin E1 protects against ischemia-reperfusion injury of the liver by inhibition of neutrophil adherence to endothelial cells. Transplantation 64: 1514–1520.
- 34. Bilzer M, Witthaut R, Paumgartner G, Gerbes AL (1994) Prevention of ischemia/reperfusion injury in the rat liver by atrial natriuretic peptide. Gastroenterology 106: 143–151.
- 35. Kiemer AK, Gerbes AL, Bilzer M, Vollmar AM (2002) The atrial natriuretic peptide and cGMP: novel activators of the heat shock response in rat livers. Hepatology 35: 88–94.
- 36. Kobayashi K, Oshima K, Muraoka M, Akao T, Totsuka O, et al. (2007) Effect of atrial natriuretic peptide on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model. World J Gastroenterol 13: 3487–3492.